TransUnion
TRU
$70.41
-1.11%
TransUnion is one of the three dominant credit bureaus in the United States, providing consumer credit information, fraud detection, marketing, and analytical services globally. The company operates as a core infrastructure player within the financial data ecosystem, with a significant international presence spanning over 30 countries. The current investor narrative is shaped by its strategic expansion in key international markets, as evidenced by its recent acquisition of majority ownership in Mexico's Buró de Crédito, and the ongoing debate around its ability to maintain growth and margins amidst competitive pressures and economic cyclicality affecting credit activity.…
TRU
TransUnion
$70.41
Related headlines
Investment Opinion: Should I buy TRU Today?
Rating: Hold. The core thesis is that TRU is a fundamentally sound company caught in a severe cyclical and sentiment downdraft, making it too early to buy but potentially offering value for patient investors if the technical picture stabilizes. This aligns with the mixed but stable analyst consensus leaning bullish/neutral.
Supporting evidence includes the compelling forward P/E of 11.82x based on a $7.92 EPS estimate, which suggests significant embedded recovery. The company's strong TTM free cash flow of $661.6M and manageable debt-to-equity of 1.16 provide financial resilience. However, these positives are counterbalanced by the severe technical downtrend (-19.1% over 1 year), elevated trailing P/E of 36.60x, and margin pressure evidenced by gross margin compression.
The thesis would upgrade to Buy if the stock establishes a firm base above its 52-week low of $65.24 and shows sequential improvement in operating margins above 18%. It would downgrade to Sell if quarterly revenue growth decelerates below 5% YoY or if forward EPS estimates are cut meaningfully below $7.50. Currently, the stock appears fairly valued to slightly overvalued on a trailing basis but undervalued on forward estimates, creating a bifurcated view that warrants caution.
Sign up to view all
TRU 12-Month Price Forecast
The outlook is bifurcated between a compelling forward valuation and severe near-term technical and fundamental headwinds. The base case of a gradual recovery towards $80 is most probable, contingent on the company hitting its EPS targets amidst a stable economic backdrop. The stance would upgrade to bullish on a confirmed breakout above the $85 resistance level with volume, signaling the downtrend has broken. It would turn bearish on a weekly close below $65, which would invalidate the value thesis and likely lead to further estimate cuts. The high free cash flow and strategic international positioning provide a foundation, but investor patience will be required.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransUnion's 12-month outlook, with a consensus price target around $91.53 and implied upside of +30.0% versus the current price.
Average Target
$91.53
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$56 - $92
Analyst target range
Analyst coverage for TRU appears limited in the provided dataset, with only 5 analysts contributing to estimates for revenue and EPS, though institutional ratings from major firms are available. The consensus sentiment leans bullish to neutral, with recent ratings including 'Overweight' from Morgan Stanley and Wells Fargo, 'Buy' from Stifel and Needham, and 'Neutral' or 'Equal Weight' from Goldman Sachs and Barclays. The average revenue estimate for the period is $6.02 billion, with a range from $5.78 billion to $6.30 billion, while the average EPS estimate is $7.92, ranging from $7.51 to $8.41. The wide target range for both revenue and EPS signals high uncertainty among analysts regarding the company's near-term performance, likely tied to macroeconomic sensitivity and integration risks from recent acquisitions. The pattern of recent ratings shows stability, with no downgrades in the latest actions, suggesting analysts are maintaining their views pending further evidence of execution on the company's strategic initiatives.
Bulls vs Bears: TRU Investment Factors
The evidence currently tilts bearish, driven by the stock's severe technical breakdown, elevated trailing valuation, and decelerating growth momentum in a volatile macro environment. The bull case rests heavily on a significant earnings rebound implied by the discounted forward P/E of 11.82x and the company's strong free cash flow for strategic maneuvering. The single most important tension in the investment debate is whether the company can deliver on the forward earnings estimates ($7.92 EPS) that justify its current price, or if continued margin pressure and cyclical headwinds will lead to further estimate cuts and multiple compression. The resolution of this earnings visibility question will determine the stock's direction.
Bullish
- Strong Forward P/E Discount: The forward P/E of 11.82x is a significant discount to the trailing P/E of 36.60x, implying the market expects a substantial earnings recovery. This forward multiple is also attractive relative to many growth stocks, suggesting a valuation floor if earnings estimates of $7.92 EPS are met.
- Robust Free Cash Flow Generation: The company generates strong free cash flow, with TTM FCF of $661.6 million. This provides ample liquidity to fund strategic acquisitions like the Buró de Crédito deal, pay dividends, and repurchase shares, supporting shareholder returns even during a downturn.
- Strategic International Expansion: The recent acquisition of majority ownership in Mexico's Buró de Crédito strengthens its Latin American footprint. This move diversifies revenue away from the dominant U.S. segment ($918.9M in Q4) and offers a long-term growth runway in underpenetrated markets.
- Analyst Consensus Remains Stable: Despite recent stock weakness, analyst ratings from major firms like Morgan Stanley and Wells Fargo remain 'Overweight' or 'Buy', with no recent downgrades. This suggests professional sentiment is holding, awaiting evidence of strategic execution.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is in a pronounced downtrend, down 19.14% over the past year and 16.81% over three months, significantly underperforming the S&P 500 by 41.34% over one year. It trades just 6.3% above its 52-week low of $65.24, indicating persistent selling pressure and a lack of positive momentum.
- Elevated Trailing Valuation & Margin Pressure: The trailing P/E of 36.60x is elevated, especially for a company with a net margin of 8.64%. Gross margin has compressed sequentially from 59.33% in Q1 2025 to 59.35% in Q4 2025, and operating income has been volatile, raising concerns about profitability sustainability.
- High Volatility & Macro Sensitivity: With a beta of 1.71, TRU is 71% more volatile than the market, amplifying downside risk in a risk-off environment. As a credit bureau, its business is cyclically sensitive to consumer credit activity, which could weaken in an economic slowdown.
- Revenue Growth Deceleration: While Q4 2025 revenue grew 12.98% YoY to $1.17B, this followed a sequential decline from Q3's $1.17B. This deceleration, coupled with high reliance on the U.S. market, raises questions about the durability of top-line growth.
TRU Technical Analysis
The stock is in a pronounced downtrend, having declined 19.14% over the past year, significantly underperforming the broader market. As of the latest data, the price of $69.32 sits near the lower end of its 52-week range, trading at approximately 20% above its 52-week low of $65.24, which suggests the stock is in a zone of potential value but remains under severe selling pressure. The recent momentum is decisively negative, with the stock down 12.51% over the past month and 16.81% over the past three months, indicating accelerating downward momentum that reinforces the longer-term bearish trend. This persistent weakness is underscored by a 1-month relative strength of -8.23% against the S&P 500, highlighting significant underperformance. Key technical support is firmly established at the 52-week low of $65.24, while resistance lies at the 52-week high of $99.39. A sustained breakdown below $65.24 would signal a continuation of the downtrend, whereas a recovery above this recent low could indicate a basing pattern. The stock exhibits high volatility with a beta of 1.71, meaning it is approximately 71% more volatile than the market, which amplifies both downside risk and potential upside during a recovery.
Beta
1.71
1.71x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$65-$99
Price range past year
Annual Return
-13.1%
Cumulative gain past year
| Period | TRU Return | S&P 500 |
|---|---|---|
| 1m | -5.5% | +0.4% |
| 3m | -19.7% | -2.0% |
| 6m | -9.4% | +4.1% |
| 1y | -13.1% | +23.9% |
| ytd | -15.5% | -0.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TRU Fundamental Analysis
Revenue growth has been positive but shows signs of deceleration; the most recent quarterly revenue was $1.17 billion, representing a year-over-year growth of 12.98%, yet this follows a sequential decline from Q3 2025's $1.17 billion. The revenue segment data reveals the U.S. Markets segment, at $918.9 million, remains the primary growth driver, significantly larger than the International segment's $255.8 million. The company is profitable, posting net income of $101.2 million in Q4 2025, translating to a net margin of 8.64%. However, profitability has been inconsistent, with gross margin compressing to 59.35% in Q4 from 59.33% in Q1 2025, and operating income of $203.6 million yielding an operating margin of 17.38%, which has fluctuated quarter-to-quarter. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.16, indicating a leveraged but manageable capital structure. Financial health is supported by strong free cash flow generation, with TTM free cash flow of $661.6 million, providing ample liquidity for dividends, share repurchases, and strategic acquisitions like the recent Buró de Crédito deal. The current ratio of 1.75 and return on equity of 10.26% reflect adequate short-term liquidity and acceptable capital efficiency.
Quarterly Revenue
$1.2B
2025-12
Revenue YoY Growth
+0.12%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$661600000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TRU Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 36.60x, while the forward P/E is significantly lower at 11.82x, indicating the market expects a substantial recovery in earnings over the next twelve months. Compared to sector averages, the trailing P/E of 36.60x is at a premium, though the forward multiple suggests convergence if earnings estimates are met. The stock also trades at a price-to-sales ratio of 3.64x and an EV/EBITDA of 14.43x, which must be evaluated in the context of its growth profile and industry peers. Historically, the current trailing P/E of 36.60x is below its own 5-year peak observed in late 2024 (e.g., 68.24x in Q4 2024) but above levels seen during stronger profitability periods in early 2025 (e.g., 27.33x in Q1 2025). This positioning in the mid-to-upper range of its historical band suggests the market is pricing in a recovery but remains cautious relative to past optimism, with significant expectations embedded in the forward earnings estimates.
PE
36.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -11x~103x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability volatility and valuation dependency on growth. The net margin of 8.64% is modest for a stock with a trailing P/E of 36.6x, creating vulnerability if earnings disappoint. Operating margins have fluctuated between 15.4% and 23.2% over the past year, indicating inconsistent cost control. Furthermore, revenue remains heavily concentrated in the U.S. Markets segment, which constituted 78% of Q4 revenue ($918.9M of $1.17B), exposing the company to domestic economic cycles.
Market & Competitive Risks are heightened by the stock's premium valuation and high volatility. The trailing P/E of 36.60x is at a premium to many industrials, risking compression if growth decelerates. The beta of 1.71 means TRU is highly sensitive to broader market swings, as evidenced by its 41.3% underperformance vs. the S&P 500 over the past year. Competitively, news highlights rivals like Upstart building their own AI tools, potentially disrupting traditional credit assessment models. Regulatory scrutiny on data privacy and credit reporting remains a persistent sector headwind.
Worst-Case Scenario involves a recessionary environment that sharply reduces credit inquiry volumes, combined with integration missteps from the Buró de Crédito acquisition. This could trigger analyst downgrades and forward EPS estimates falling towards the low end of $7.51. In this scenario, the stock could re-test and break its 52-week low of $65.24, potentially falling to levels implied by a high-single-digit forward P/E on reduced earnings, representing a downside of 20-30% from the current price near $69. The historical max drawdown of -33.72% provides a realistic gauge for potential loss severity in an adverse cycle.
FAQ
The key risks are, in order of severity: 1) Cyclical/Macro Risk: High beta (1.71) and sensitivity to consumer credit cycles could lead to further earnings misses in a slowdown. 2) Execution Risk: Failure to integrate the Buró de Crédito acquisition or sustain international growth could impair the long-term thesis. 3) Valuation Compression Risk: If forward EPS estimates of $7.92 are cut, the attractive forward P/E expands, potentially leading to further price declines. 4) Technical Risk: The stock is in a confirmed downtrend and a break below $65.24 could trigger accelerated selling.
The 12-month forecast is a range of scenarios. The base case (55% probability) sees the stock recovering to $75-$85 as it meets consensus EPS estimates of ~$7.92, justifying its forward multiple. The bull case (25%) could drive the stock to $95-$105 on better-than-expected international growth and multiple expansion. The bear case (20%) risks a fall to $60-$68 if economic weakness triggers estimate cuts. The most likely outcome is the base case, hinging on the critical assumption that the company can deliver on its current forward earnings guidance amidst a stable economic backdrop.
TRU's valuation is schizophrenic: it appears significantly overvalued on a trailing basis with a P/E of 36.60x and a P/S of 3.64x, but potentially undervalued on a forward basis with a P/E of 11.82x. This dichotomy reflects the market's expectation of a sharp earnings recovery. Compared to its own history, the trailing P/E is in the mid-to-upper range, suggesting caution relative to past optimism. The valuation implies the market is paying a fair price for future growth but is punishing the stock heavily for recent operational volatility and macro fears.
TRU presents a high-risk, potentially high-reward opportunity that is not suitable for all investors. For a value-oriented investor with a 2-3 year horizon, the forward P/E of 11.82x and strong free cash flow generation are attractive. However, given the severe downtrend (-19% over 1 year), high beta of 1.71, and near-term earnings uncertainty, it is not a good buy for short-term traders or risk-averse investors. A prudent approach would be to wait for a confirmed stabilization in price above the $65 support level and improving quarterly momentum before establishing a position.
TRU is unsuitable for short-term investment due to its high volatility (beta 1.71), lack of positive momentum, and sensitivity to quarterly earnings surprises. It is better suited for a long-term (3+ year) investor who believes in the resilience of its credit bureau oligopoly and its international growth strategy. The modest dividend yield of 0.54% does not support an income strategy. Given the need for its strategic initiatives to bear fruit and for the cycle to turn, a minimum holding period of 18-24 months is suggested to allow the investment thesis to play out.